This phase II trial tests how well itacitinib works in in patients with immune related adverse events (irAEs) arising from immune checkpoint inhibitors (ICI) that do not respond to steroids (steroid refractory). Steroids are the usual treatment for these side effects. However, sometimes steroids do not improve or fix the side effects. Giving itacitinib may be effective in treating patients with known or suspected problems coming from ICIs, that do not resolve or improve with steroids, by reducing the patients immune system response that can cause the irAEs.

开始日期2025-01-30

申办/合作机构

The Vanderbilt-Ingram Cancer Center

[+1]

CTIS2022-501661-47-00

/ Recruiting临床2期

INCB 39110-801 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110) - INCB 39110-801

开始日期2023-08-23

申办/合作机构

Incyte Corp.

NCT05823571

/ Recruiting临床1期IIT

Phase 1a/1b Study of Itacitinib (INCB039110) for Cytokine Release Syndrome Prevention and Minimization of Immunosuppression Following Nonmyeloablative Related Partially HLA-mismatched Peripheral Blood Stem Cell Transplant (PBSCT) With High-dose Posttransplantation Cyclophosphamide in Older Patients (Age 60 Years)

This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell transplantation (PBSCT; also known as a 'mini' transplant) to help prevent certain complications such as cytokine release syndrome (CRS) for patients with blood cancers, using peripheral blood from a relative. The investigators will also examine if by using itacitinib the investigators can reduce the duration of MMF (other immune suppressive drug administration posttransplant).

开始日期2023-07-06

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

[+1]

100 项与伊他替尼相关的临床结果

登录后查看更多信息

100 项与伊他替尼相关的转化医学

登录后查看更多信息

100 项与伊他替尼相关的专利（医药）

登录后查看更多信息

项与伊他替尼相关的文献（医药）

2025-01-02·Nanomedicine

Pluronic F127/lecithin PLGA nanoparticles as carriers of monocyte-targeted jakinibs: a potential therapeutic platform

Article

作者: Álvarez, Karen ; Orozco, Víctor H ; Giraldo, Luis F ; Rojas-López, Mauricio ; Cruz, Jennifer T ; Vásquez, Gloria

Aim: In this study, PLGA nanoparticles (PNPs) emulsified in Pluronic F127 (F127)/Lecithin (LEC) were designed to load Itacitinib (ITA), a selective JAK1 inhibitor, for targeting human monocytes.Materials & methods: The physicochemical characteristics of empty and ITA-loaded F127/LEC PNPs were analyzed. The binding and internalization of NPs in leukocytes were evaluated. The effect of NPs on monocyte activation and JAK1 inhibition was assessed.Results: F127/LEC PNPs were selectively bound and internalized by monocytes, sparing other leukocytes. ITA-F127/LEC PNPs significantly dampened monocyte activation. They also inhibited the monocyte's ability to promote T-cell proliferation and inhibited proinflammatory cytokine production.Conclusion: ITA-loaded F127/LEC PNPs showed potential for monocyte-targeted therapy, offering new avenues for disease treatment.

2024-12-01·Current Hematologic Malignancy Reports

Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease

Review

作者: Abedin, Sameem ; Hamadani, Mehdi

PURPOSE OF REVIEW:

Graft-versus-host disease (GVHD) is a serious complication after allogeneic HCT. Recently, several pivotal studies have been conducted demonstrating significant improvements in the management of GVHD. Here, we review important trials pertaining to GVHD prevention, acute GVHD treatment, and treatment of steroid refractory acute and chronic GVHD.

RECENT FINDINGS:

Clinical trials in preventing GVHD demonstrate lower rates of severe acute GVHD and chronic GVHD with post-transplant cyclophosphamide. For acute GVHD, lower risk acute GVHD appears amenable to steroid-sparing therapies, such as sirolimus and itacitinib. Combinations with novel agents such as itolizumab appear promising for high risk acute GVHD. For steroid-refractory acute GVHD, ruxolitinib should be considered first line therapy. For chronic GVHD requiring therapy beyond steroids, ruxolitinib, belumosudil, and ibrutinib are now available and should be considered. Increasingly, GVHD has become a manageable complication after allogeneic HCT potentially translating to greater success with allogeneic HCT in the future.

2024-11-16·Future Oncology

Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: Phase 1b trial (JAKAL)

Article

作者: Sharma, Rohini ; Benartzi, Charlotte Wilhelm ; Troiani, Alessandro ; Ward, Caroline ; Martinez, Maria ; Pinato, David J

Overactivation of the JAK/STAT pathway is one of the drivers for the pathophysiology of hepatocellular carcinoma (HCC). We propose a Phase Ib study to evaluate the safety and efficacy of itacitinib, a selective JAK1 inhibitor, as a second-line treatment for patients with advanced or metastatic HCC.Twenty-five patients will receive 400 mg itacitinib orally daily, 28-day cycle. Safety will be reviewed prior to each cycle. Tumor response assessed every 2 months until disease progression, death or withdrawal. Tumor biopsies and blood samples will be taken for presence of JAK1 mutations.Activation of JAK/STAT pathway drives HCC development and is associated with immunotherapy resistance. Itacitinib is hypothesized to be safe and effective in HCC patients that have progressed after first-line therapies.Clinical Trial Registration: EudraCT: 2017-004437-81 NCT04358185 (ClinicalTrials.gov).

项与伊他替尼相关的新闻（医药）

2025-01-21

·ioncology

2024 WCLC 晚期肺癌一线治疗进展合集

点上方蓝字“ioncology”关注我们，然后点右上角“…”菜单，选择“设为星标” 前言：2024年世界肺癌大会（WCLC）上公布了多项晚期非小细胞肺癌（NSCLC）一线治疗重磅研究成果，《肿瘤瞭望》特将重要研究进行回顾整理，以飨读者。 01 埃万妥单抗联合Lazertinib与奥希替尼一线治疗携带EGFR突变NSCLC患者的疗效及安全性：一项III期临床研究的长期随访结果奥希替尼是携带EGFR敏感突变患者的一线标准治疗，Lazertinib是三代EGFR-酪氨酸激酶抑制剂（TKI）类药物，埃万妥单抗是一款靶向EGFR和c-MET的双特异性抗体药物，MARIPOSA研究旨在探索双药联合治疗相较于奥希替尼单药一线治疗携带EGFR敏感突变晚期NSCLC患者的疗效及安全性。在前期公布的数据中，联合治疗相较于奥希替尼单药展示出了更好的无进展生存期（PFS）的数据，本次旨在公布其长期随访结果和颅内随访结果。本次数据公布时，两组颅内PFS分别为24.9个月和22.2个月，HR=0.82， P=0.165，颅内缓解持续时间（DoR）分别为未达到和24.2个月，中位至治疗终止时间分别为26.3个月和22.6个月，HR=0.80，P=0.014，至后线开启治疗时间分别为30.0个月和24.0个月，HR=0.77，P=0.005。联合治疗组和单药治疗组分别有41%和45%的患者接受含铂双药治疗，分别有12%和20%的患者接受含铂双药联合免疫或抗血管生成治疗，分别有27%和16%的患者接受了其他三代靶向药物治疗。两组PFS分别为未达到和32.4个月，HR=0.73，P=0.004。两组中位总生存期（OS）分别为未达到和37.3个月，HR=0.77，P=0.019。两组更新后的OS数据本届WCLC还公布了该研究中Lazertinib与奥希替尼比较的疗效数据，研究显示，奥希替尼和Lazertinib的客观缓解率（ORR）分别为85%和83%，P=0.57，均有4%的患者达到病理完全缓解（pCR），中位PFS分别为16.6个月和18.5个月，HR=0.98，P=0.86。基线有脑转移、基线有可测量循环肿瘤DNA以及基线合并TP53共突变的三个高危因素组患者，HR值分别为0.90、0.88和0.85，差异均无统计学意义。中位至症状恶化时间分别为29.3个月和未达到，HR=0.85，P=0.27。首次中期分析时，两组中位OS均未达到，HR=1.0。两组OS数据严重不良反应发生率分别为33%和35%，并分别导致了7%和6%的患者出现死亡事件。奥希替尼组腹泻 (44% vs 32%)，血小板降低(20% vs 9%)，中性粒细胞下降(13% vs 3%)发生率更高，而Lazertinib组皮疹(45% vs 31%)，肌肉痉挛(23% vs 7%)发生率更高。 02 SH-1028 vs 吉非替尼一线治疗EGFR突变阳性的NSCLC患者的疗效及安全性：一项多中心、双盲、随机III期临床研究 SH-1028是一款三代EGFR-TKI类药物，可以克服继发性T790M突变。本研究旨在比较该药与一代靶向药物吉非替尼的疗效及安全性。研究纳入局部晚期或转移性NSCLC患者，携带19del或21L858R突变，符合入组标准的患者按2:1的比例随机分为SH-1028 200mg，口服，每日一次，或吉非替尼250mg，口服，每日一次，主要研究终点为独立评审委员会评估的PFS，次要研究终点包括ORR、DoR、安全性等。最终，两组分别入组162例和83例患者，基线特点均衡可比。入组时，两组分别有33.3%和34.9%的患者有脑转移，两组中位PFS分别为19.3个月和9.8个月，HR=0.46，P＜0.001，中位DoR分别为20.7个月和11.1个月，12个月DoR率分别为68.4%和40.6%，24个月DoR率分别为38.5%和10.3%，疾病控制率（DCR）分别为93.8%和97.6%。两组中位PFS 新药组较常见的3级以上不良反应包括白细胞计数下降2.5%，血肌酸激酶升高1.9%、中性粒细胞下降1.9%；吉非替尼组较常见的3级及以上不良反应包括谷丙转氨酶升高7.2%，谷草转氨酶升高4.8%和皮疹2.4%。这项研究发现，SH-1028相较于一代靶向药物吉非替尼一线治疗治疗携带EGFR驱动基因突变的晚期NSCLC患者具有更好的疗效及安全性。 03 射频消融联合免疫治疗提高晚期且有寡残留NSCLC患者的疗效：一项II期临床研究 20%的晚期NSCLC患者经过免疫检查点抑制剂治疗后可形成寡残留状态，部分患者接受局部治疗后可观察到远隔效应，本研究旨在探索晚期接受免疫治疗后形成寡残留的患者，接受局部治疗的疗效和安全性。这是一项随机对照临床研究，纳入局部晚期或转移性NSCLC患者，患者一线接受免疫单药或免疫联合化疗，符合入组标准的患者按2:1的比例进行分组，一组接受免疫维持治疗，另一组在此基础上针对寡残留病灶接受局部治疗，主要研究终点为PFS。最终，免疫治疗组和联合治疗组分别入组42例和20例患者，腺癌占比分别为59.5%和65.0%，PD-L1≥50%的患者占比分别为23.8%和15%。联合治疗组和免疫治疗组中位PFS分别为26.7个月和11.7个月，2年PFS率分别为53%和10%，24个月OS率分别为94%和60%。两组PFS及OS 亚组分析显示，不同临床病理特点的患者都可以从这一治疗中有获益，加上局部治疗后有1例患者出现3级气胸。 04 帕博利珠单抗联合Itacitinib治疗PD-L1表达的NSCLC患者的疗效及安全性：一项长期随访数据基础研究显示，JAK抑制剂可以发挥免疫刺激以及免疫抑制的双向调节作用，临床前数据显示，在恶性黑色素瘤中，免疫检查点抑制剂联合延迟给药的JAK抑制剂相较于同步给药具有更好的疗效。本研究旨在探索帕博利珠单抗联合延迟给药的JAK抑制剂能否提高患者疗效。这项研究纳入初治、转移性NSCLC患者，患者PD-L1≥50%。符合入组标准的患者首先给予两周期帕博利珠单抗治疗，在后续两周期帕博利珠单抗治疗的同时给予JAK抑制剂治疗，随后给予帕博利珠单抗维持治疗，直至疾病进展，主要研究终点为12周的ORR。最终，研究共入组23例患者，12个月的ORR为62%，中位PFS为15.6个月，PD-L1表达在50%~89%和90%~100%的患者，中位PFS分别为6.97个月和23.41个月，中位OS为53.4个月。患者的PFS及OS 较常见的与帕博利珠单抗相关的3级及以上不良反应包括：腹泻，肺炎，重症肌无力，各有1例患者；与Itacitinib有关的不良反应多数为1～2级。 05 HR-20013预防及治疗铂类药物诱导的恶心及呕吐的疗效及安全性：一项III期临床研究以顺铂为基础的化疗是临床常用的治疗选择，但恶心呕吐可能会影响患者的主观体验。目前，临床常用的药物包括NK1受体拮抗剂，5HT-3阻断剂以及地塞米松，尽管这是指南推荐的治疗方案，但实际执行率并不高。本研究旨在探索HR-20013在预防铂类药物诱导的恶心及呕吐方面的疗效及安全性。研究纳入组织病理学确认的初治晚期实体瘤患者，符合入组标准的患者按1:1的比例随机分为HR-20013联合地塞米松或帕洛诺司琼联合地塞米松联合福沙匹坦治疗，主要研究终点为第1周期0~120小时的完全缓解（CR）率，该研究为非劣效设计，两组CR率预设为75%，非劣效界值为10%，把握度85%，单侧α为0.025。最终，两组分别入组373例和377例患者，基线特点均衡可比。第一周期CR率分别为77.7%和78.2%。0~168小时CR率分别为76.4%和75.1%，急性期CR率分别为91.2%和89.9%。全因不良反应发生率分别为27.1%和27.16%，因不良反应而导致治疗终止或治疗中断的比例分别为1.3%和0.5%。两组不同阶段的CR率这项研究证实了HR-20013联合地塞米松非劣效于当前的标准治疗。 06 戈沙妥珠单抗联合帕博利珠单抗联合卡铂一线治疗转移性NSCLC患者的疗效及安全性：EVOKE-02研究该研究纳入初治、转移性NSCLC患者，符合入组标准的患者按照PD-L1表达水平及组织病理类型分为4个队列：队列a为PD-L1≥50%的NSCLC患者，入组30例；队列b为PD-L1＜50%的NSCLC患者，入组60例；队列c纳入非鳞NSCLC患者，无论PD-L1表达水平，入组54例患者；队列d纳入鳞癌患者，无论PD-L1表达水平，入组41例患者。队列c或队列d接受7.5mg/kg或者10mg/kg的戈沙妥珠单抗联合帕博利珠单抗及卡铂治疗。主要研究终点为独立评审委员会评估的ORR。本次报道了队列c和队列d的数据。最终，两组PD-L1＜50%的患者占比分别为85.2%和90.2%。ORR分别为45.1%和39.0%，中位PFS分别为8.1个月和8.3个月。中位DoR分别为未达到和11.5个月。10mg/kg和7.5mg/kg戈沙妥珠单抗治疗组的患者，3级不良反应发生率分别为93.1%和86.4%，严重不良反应发生率分别为62.1%和54.5%，因不良反应而导致死亡的患者占比分别为10.3%和7.6%。 07 SAF-189s或克唑替尼一线治疗ALK融合阳性晚期NSCLC患者的疗效及安全性：一项随机、开放标签、III期临床研究 5%左右的晚期NSCLC患者携带ALK基因融合，目前，包括克唑替尼、阿来替尼、布格替尼、恩沙替尼、赛瑞替尼、伊鲁阿克、洛拉替尼等药物均已经被批准在这部分患者的一线应用。SAF-189s是一款新型下一代TKI类药物，本研究旨在探索该药与克唑替尼相比的疗效及安全性。研究纳入局部晚期或转移性NSCLC患者，按1:1的比例随机分为克唑替尼250mg，口服，每日两次或研究药物160mg，口服，每日一次，治疗主要研究终点为独立评审委员会评估的PFS。最终，SAF-189s组和克唑替尼组分别入组139例和136例患者。两组基线特点均衡可比。基线时，两组分别有28.8%和27.2%的患者有脑转移，中位PFS分别为未达到和13.93个月，HR=0.23。中位至颅内进展时间分别为未达到和19.32个月，HR=0.04。两组中位OS分别为未达到和24.94个月，HR=0.6，P=0.0723，两组ORR分别为92.8%和80.9%，中位响应持续时间分别为未达到和15.93个月，颅内ORR分别为100%和50%。3级以上治疗相关不良反应发生率分别为37.7%和55.6%，严重不良反应发生率分别为15.9%和11.9%，因不良反应而导致治疗中断的患者占比分别为26.8%和35.6%，剂量降低的患者占比分别为23.9%和37.8%，并分别有3.6%和2.2%的患者因不良反应而导致永久性终止治疗。两组的中位PFS 这项研究显示，针对ALK融合阳性的晚期NSCLC患者，一线给予SAF-189s相较于克唑替尼具有更好的疗效。 08 Rilvegostomig——一款针对PD-1和TIGIT的双特异性抗体，在初治且PD-L1表达1-49%或≥50%的晚期NSCLC患者中疗效及安全性 Rilvegostomig是一款针对PD-1和TIGIT的双抗，在体外研究中观察到了抗肿瘤活性，本研究旨在探索该药在初治、PD-L1≥1%的晚期NSCLC患者的疗效及安全性。研究纳入的患者允许接受最多一线化疗药物治疗，但不允许接受靶向治疗，符合入组标准的患者按1:1的比例，随机分为750mg，每三周一次或1500mg，每三周一次。两组均入组31例患者，主要研究终点为ORR。最终，两组分别有9.7%和6.5%的患者既往接受过化疗，脑转移患者占比分别为29.0%和22.6%。接受750mg，每三周一次治疗的患者，PD-L1表达为1~49%和≥50%的患者的ORR分别为29.0%和61.8%，中位PFS分别为6.0个月和10.2个月；接受1500mg，每三周治疗一次且PD-L1≥50%的患者，ORR为36.7%。没有4级及以上治疗相关不良反应出现，3级以上免疫相关不良反应发生率为2.1%。 09 Prolgolimab联合化疗一线治疗晚期非鳞、NSCLC患者的疗效及安全性 Prolgolimab是一款针对PD-1的免疫检查点抑制剂，本研究旨在探索该药联合化疗在驱动基因突变阴性晚期NSCLC患者中的疗效及安全性。研究纳入非鳞NSCLC患者且至少有一个远处转移病灶，驱动基因突变阴性，符合入组标准的患者按1:1的比例随机接受培美曲塞联合铂类，或在此基础上联合Prolgolimab治疗(3mg/kg)，主要研究终点为OS。最终，两组分别入组143例和149例患者，基线分别有10.5%和15.4%的患者有脑转移。PD-L1≥1%的患者占比分别为60.1%和59.7%，两组中位OS分别为未达到和14.8个月，HR=0.48，P=0.001；PD-L1≥1%的患者，两组中位OS分别为未达到和15.7个月，HR=0.49；PD-L1表达1~49%的患者，两组中位OS分别为未达到和24.1个月，HR=0.58；PD-L1＜1%的患者，两组中位OS分别为未达到和14.6个月，HR=0.53；PD-L1≥50%的患者，两组中位OS分别为未达到和9.6个月，HR=0.31。两组中位PFS分别为7.7个月和5.5个月，HR=0.65，P=0.004；PD-L1≥50%的患者，两组中位PFS分别为8.9个月和5.5个月，HR=0.35，PD-L1＜1%的患者，两组中位PFS分别为5.6个月和4.4个月HR=0.73；PD-L1在1~49%的患者，两组中位PFS分别为10.0个月和5.8个月，HR=0.65。两组中位OS 两组免疫相关3级及以上不良反应发生率分别为8.4%和2.7%。 10 西米普利单抗单药一线治疗PD-1≥50%的晚期NSCLC患者的疗效及安全性：EMPOWER-Lung-01研究5年随访数据 EMPOWER-Lung-01研究探索了西米普利单抗在驱动基因突变阴性且PD-L1≥50%的晚期NSCLC患者中的疗效及安全性。该研究中，符合入组标准的患者按1:1的比例随机分为4~6周期含铂双药化疗或西米普利单抗(350mg，静滴，每三周一次)。主要研究终点为OS。免疫治疗组疾病进展后，若研究者认为有获益，可继续接受免疫治疗，即在此基础上联合4周期化疗。最终，免疫治疗组和化疗组分别入组284例和281例患者，中位OS分别为26.1个月和13.3个月，HR=0.559，P＜0.001。患者的OS数据中位PFS分别为8.1个月和5.3个月，HR=0.50，P＜0.001，ORR分别为46.5%和20.6%。两组2年、3年、4年OS率分别为52.6% vs 32.1%；40.8% vs 21.5%；29.0% vs 15.0%；1年、2年、3年的PFS率分别为41.6% vs 7.2%、26.6% vs 4.7%、20.8% vs 3.1%，不同临床病理特点的亚组都可以从这一治疗中获益。中位响应持续时间分别为24.1个月和5.9个月。PD-L1表达50~60%、60~90%和≥90%的患者，化疗组的中位OS分别为14.0个月、11.2个月和13.7个月，而在免疫单药组分别为19.5个月、26.2个月和38.8个月。3级以上全因不良反应发生率分别为45.8%和51.6%，治疗相关3级以上不良反应发生率分别为18.3%和39.9%。75例患者疾病进展后接受免疫联合化疗，这部分患者自化疗开始，中位PFS和OS分别为6.5个月和15.1个月；从随机开始，中位OS为27.4个月。（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果临床3期免疫疗法上市后研究

2024-12-09

·drugs

Itacitinib Helps Prevent Graft Versus Host Disease in Stem Cell Transplant Recipients

MONDAY, Dec. 9, 2024 -- For patients with haploidentical hematopoietic cell transplantation (haplo-HCT), the addition of itacitinib to standard graft versus host disease (GvHD) prophylaxis is well tolerated and results in low rates of cytokine release syndrome (CRS), according to a study published online Nov. 2 in Blood . Noting that posttransplant cyclophosphamide (PtCy) has improved GvHD prophylaxis in haplo-HCT, but that patients continue to experience life-threatening complications, Ramzi Abboud, M.D., from the Washington University School of Medicine in St. Louis, and colleagues examined the effect of adding the JAK-1 selective inhibitor itacitinib to PtCy-haplo-HCT in an open-label, single-arm study. Forty-two patients were treated with itacitinib 200 mg daily from day −3 to +100 or +180. The researchers found that itacitinib resulted in low CRS grades; 22, 78, and 0 percent of patients had grades 0, 1, and 2 to 5, respectively. No cases of primary graft failure were reported. At day +100, the cumulative incidence of grade 2 acute GvHD was 21.9 percent; no patients developed grade 3 to 4 acute GvHD at day +180. There was a 5 percent one-year cumulative incidence of moderate or severe chronic GvHD. At two years, the cumulative incidence of relapse was 14 percent. At one year, overall survival was 80 percent. At day 180, the cumulative incidence of nonrelapse mortality was 8 percent. "We saw no severe GvHD, and the rates of relapse were lower than expected in these high-risk patients," senior author John F. DiPersio, M.D., Ph.D., also from the Washington University School of Medicine, said in a statement. "Low GvHD rates and low relapse resulted in very encouraging survival for the patients in this study." Incyte Corporation provided the itacitinib and funding for the study.

临床结果细胞疗法

2024-11-21

·Business Wire

City of Hope Reveals New Data on Cancer Immunotherapies, Microbiome and Other Innovative Topics at 2024 American Society of Hematology (ASH) Annual Meeting

LOS ANGELES--( BUSINESS WIRE )-- City of Hope ® , one of the largest and most advanced cancer research and treatment organizations in the United States and ranked among the nation’s top 5 cancer centers by U.S. News & World Report, announced today that its doctors and scientists will take part in 100 oral and poster presentations, scientific symposia/workshops, education programs and other events at ASH annual meeting from Dec. 7 to 10 in San Diego. City of Hope in ASH Press Program Two City of Hope researchers will present at ASH press briefings , and one of its leaders is a senior author on an abstract that will be discussed in the press program as well. Title: Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical Gvhd Models Oral Abstract Number: 259 Press Briefing Date/Time and Embargo Lift Time: Saturday, Dec. 7, 7:15 a.m. PST Presenter: Jenny Paredes , Ph.D., City of Hope staff scientist, who will also receive an ASH Outstanding Abstract Achievement Award for this research Title : A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma Oral Abstract Number: 671 Press Briefing Date/Time and Embargo Lift Time: Saturday, Dec. 7, 7:15 a.m. PST City of Hope Senior Author: Marcel van den Brink , M.D., Ph.D., president, City of Hope Los Angeles/City of Hope National Medical Center and Deana and Steve Campbell Chief Physician Executive Distinguished Chair in Honor of Alexandra Levine, M.D. Title: Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1 Oral Abstract Number: 883 Press Briefing Date/Time and Embargo Lift Time: Sunday, Dec. 8, 8 a.m. PST Presenter: Alexey Danilov , M.D., Ph.D., City of Hope Marianne and Gerhard Pinkus Professor in Early Clinical Therapeutics, and associate director, Toni Stephenson Lymphoma Center City of Hope ASH Oral Presentations In addition, City of Hope doctors will present 22 oral abstracts with the following highlights: Title: 980 Results From the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients With Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization Session Date and Time: Monday, Dec. 9, 4:45 p.m. PST Presenter: Jasmine Zain , M.D., City of Hope professor, Division of Lymphoma, and director, T Cell Lymphoma Program Title: 468 Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients With Refractory/Advanced Cutaneous T Cell Lymphoma Session Date and Time: Sunday, Dec. 8, 10:45 a.m. PST Presenter: Christiane Querfeld , M.D., Ph.D., City of Hope professor, Division of Dermatology, and director, Cutaneous Lymphoma Program Title: 211 Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients With Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia Session Date and Time: Saturday, Dec. 7, 2 p.m. PST Presenter: Ibrahim Aldoss , M.D., City of Hope associate professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation Title: 524 Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients With Relapsed Refractory Transformed Indolent Lymphoma Session Date and Time: Sunday, Dec. 8, 9:45 a.m. Presenter: Swetha Kambhampati Thiruvengadam , M.D., City of Hope assistant professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation Title: 210 Disrupting Mitochondrial Dynamics and Metabolism in Leukemic Stem Cells through Mitochondrial PCNA Inhibition: The Role of AOH1996 Session Date and Time: Saturday, Dec. 7, 3:15 p.m. PST Presenter: Hyunjun Kang, Ph.D., City of Hope staff scientist, Department of Hematologic Malignancies Translational Science Title: 1043 Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis After Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF) Session Date and Time: Monday, Dec. 9, 5:30 p.m. PST Presenter: Haris Ali , M.D., City of Hope associate professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, and section leader, Myeloproliferative Neoplasms Program Title: 966 CD19-CAR T Cells As Definitive Consolidation for Older Adults With B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study Session Date and Time: Monday, Dec. 9, 5:45 p.m. PST Presenter: Ibrahim Aldoss , M.D., City of Hope associate professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation Title: 685 The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704 Session Date and Time: Sunday, Dec. 8, 4:30 p.m. PST Senior Author: Andrew Artz , M.D., M.S., City of Hope professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, and director, Aging and Blood Cancers Program City of Hope doctors will also lead in the following ASH events: The 13th Annual BMT & Cell Therapy Winter Workshop , co-chaired by Dr. Van den Brink, will be held on Friday, Dec. 6, 2024, prior to the ASH conference. The workshop focuses on innovative research pertinent to hematopoietic stem cell transplantation and cell therapy. Dr. Van den Brink will also speak at a scientific symposium titled “Placing the Brakes on Accelerated Aging” about targeting rejuvenation therapies to decelerate aging on Monday, Dec. 9, 2024. Jianjun Chen , Ph.D., Simms/Mann Family Foundation Chair in Systems Biology, will speak at a scientific workshop titled “Therapy Resistance Mechanisms in Blood Malignancies Program” about RNA modification and therapy resistance in acute leukemia on Friday, Dec. 6, 2024. About City of Hope City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest and most advanced cancer research and treatment organizations in the U.S., and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines , as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center that is ranked top 5 in the nation for cancer care by U.S. News & World Report at its core, City of Hope’s uniquely integrated model spans cancer care, research and development, academics and training, and a broad philanthropy program that powers its work. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHope™ . For more information about City of Hope, follow us on Facebook , X , YouTube , Instagram and LinkedIn .

临床2期临床结果免疫疗法ASH会议细胞疗法

100 项与伊他替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10944	-	-	DB12154

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性移植物抗宿主病	临床3期	美国	Incyte Corp.	2017-07-19
急性移植物抗宿主病	临床3期	澳大利亚	Incyte Corp.	2017-07-19
急性移植物抗宿主病	临床3期	奥地利	Incyte Corp.	2017-07-19
急性移植物抗宿主病	临床3期	比利时	Incyte Corp.	2017-07-19
急性移植物抗宿主病	临床3期	捷克	Incyte Corp.	2017-07-19
急性移植物抗宿主病	临床3期	芬兰	Incyte Corp.	2017-07-19
急性移植物抗宿主病	临床3期	法国	Incyte Corp.	2017-07-19
急性移植物抗宿主病	临床3期	德国	Incyte Corp.	2017-07-19
急性移植物抗宿主病	临床3期	希腊	Incyte Corp.	2017-07-19
急性移植物抗宿主病	临床3期	以色列	Incyte Corp.	2017-07-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04339101 (1043, ASH2024)	临床2期	骨髓纤维化 \| 急性白血病 \| 骨髓增生异常综合征 HGF \| IL17 \| TNFaR ... 更多	59	Itacitinib + Tacrolimus/Sirolimus	繭築網鬱鏇糧壓製窪網(膚醖憲遞壓積獵鬱憲簾) = 餘鑰窪齋觸憲製膚憲鬱鹽淵觸鏇製選淵餘獵憲 (壓廠憲襯鬱願獵積觸鹹, 41 ~ 66) 更多	积极	2024-12-09
				Tacrolimus/Sirolimus	繭築網鬱鏇糧壓製窪網(膚醖憲遞壓積獵鬱憲簾) = 夢觸築衊選窪繭襯蓋鬱鹽淵觸鏇製選淵餘獵憲 (壓廠憲襯鬱願獵積觸鹹 )
NCT04200365 (CTgov)	临床2期	慢性移植物抗宿主病 \| 类固醇难治性移植物抗宿主病	15	Itacitinib	網鹹艱鬱網願憲簾觸襯(網餘選網觸願鹽襯構積) = 積鬱壓蓋醖鏇繭艱齋遞鑰遞憲願鏇鏇壓製簾鹽 (獵膚獵襯窪夢醖鑰鏇夢, 窪齋網淵壓壓襯鏇壓鑰 ~ 鏇夢鹹鹽顧衊醖鏇鏇簾) 更多	-	2024-11-06
NCT04629508 (CTgov)	临床2期	真性红细胞增多症 \| 原发性血小板增多症后骨髓纤维化 \| 真性红细胞增多症后骨髓纤维化 ... 更多	4	Itacitinib	遞窪網齋構淵觸鹹構艱(齋積築鹽顧廠顧醖壓糧) = 淵獵簾鏇願窪觸窪蓋選醖築獵顧觸鬱鏇淵艱齋 (願壓醖餘衊顧選淵簾積, 製淵衊遞壓製獵襯齋醖 ~ 淵顧夢夢鬱艱築選膚鑰) 更多	-	2024-09-19
NCT03425006 (WCLC2024) 人工标引	临床2期	PD-L1阳性肺癌一线 PD-L1 Positive	23	Pembrolizumabitacitinib	齋壓遞窪膚鹹糧蓋簾餘(膚製齋糧鏇願願夢製淵) = 3 patients stopped the trial due to pembrolizumab toxicity (1), CNS progression after pembrolizumab (1) and patient decision (1). 範鏇醖製鹹鬱簾膚衊淵 (夢鹽遞鬱顧範簾簾窪顧 )	积极	2024-09-08
NCT04071366 (phase 2 study of itacitinib for the prevention of cytokine release syndrome (CRS) induced by immune effector cell (IEC) therapy \| INCB 39110-211, CTgov)	临床2期	细胞因子释放综合征	112	Itacitinib+Kymriah (Part 1: Itacitinib 200 Milligrams (mg) QD + Kymriah)	願夢憲憲構積構顧廠鏇(獵網顧憲選廠網範獵鬱) = 築鏇願廠繭鬱網夢壓憲糧積築獵衊遞鹽餘餘觸 (壓醖鏇觸襯鏇鑰網鑰壓, 構壓鬱鹽築壓餘餘艱觸 ~ 醖遞網簾願選觸網鹽餘) 更多	-	2024-03-26
				Itacitinib+Tecartus (Part 1: Itacitinib 200 mg QD + Tecartus)	願夢憲憲構積構顧廠鏇(獵網顧憲選廠網範獵鬱) = 蓋衊範觸範遞襯艱鹹製糧積築獵衊遞鹽餘餘觸 (壓醖鏇觸襯鏇鑰網鑰壓, 獵網醖構鑰艱襯觸繭憲 ~ 醖築鹽簾鹹獵網衊糧願) 更多
NCT03584516 (GRAVITAS-309, Tandem Meetings ASTCT and CIBMTR2024) 人工标引	临床2/3期	慢性移植物抗宿主病一线 elafin \| osteopontin \| C-X-C motif chemokine ligand (CXCL) 9 ... 更多	-	Itacitinib 300 mg once daily	鹽顧繭蓋築繭構繭糧選(獵齋壓遞鬱廠鹹襯簾選) = 醖鑰願齋壓夢壓艱獵構壓範構鏇構遞積壓蓋蓋 (構餘壓願願網鏇選鏇築 )	积极	2024-02-01
				Itacitinib 400 mg once daily	鹽顧繭蓋築繭構繭糧選(獵齋壓遞鬱廠鹹襯簾選) = 淵獵製獵淵繭鑰醖夢壓壓範構鏇構遞積壓蓋蓋 (構餘壓願願網鏇選鏇築 ) 更多
NCT04446182 (FLIGHT, CTgov)	临床2期	慢性移植物抗宿主病	3	itacitinib	艱淵網夢簾鑰餘糧壓築(窪願繭願糧壓襯鑰遞網) = 繭網鏇衊夢鬱積餘廠構糧簾衊衊鹹餘選鏇窪鬱 (壓繭憲鹹淵齋網遞醖淵, 積廠範繭壓選遞鏇繭醖 ~ 齋憲築遞窪餘範鬱顧壓) 更多	-	2024-01-22
NCT02646748 (Pubmed \| Cancer Res Commun)	临床1期	实体瘤	159	Itacitinib	廠築襯夢衊網積鹹衊齋(衊願積襯築網繭憲鑰範) = Most common itacitinib treatment-related adverse events (TRAE) were fatigue, nausea, and anemia. 鑰範製壓窪艱壓窪鹹膚 (衊壓鑰簾壓鬱艱壓窪顧 ) 更多	不佳	2023-12-19
				Parsaclisib
NCT03755414 (ASH2023) 人工标引	临床1期	细胞因子释放综合征 \| 移植物抗宿主病	42	Itacitinib 200 mg/day	壓繭積蓋簾鬱遞選構餘(鹹願鹹壓醖醖願選糧鏇) = 觸願遞顧衊衊繭遞衊簾鏇淵窪鑰願鏇選構積願 (醖積選願艱夢襯網簾糧 ) 更多	积极	2023-12-10
NCT04071366 (INCB 39110-211, ASH2023)	临床2期	细胞因子释放综合征	47	Itacitinib 200 mg	衊襯鹹範醖醖遞衊餘膚(簾餘衊憲鏇壓願鹽顧艱): P-Value = 0.003	-	2023-12-09
				Placebo